UNLOCKING THE POTENTIAL OF THE IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal of action approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

The Latest News

November 10, 2020

Immunophotonics Announces First Patient Treated in Swiss Clinical Trial

ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the...
Read More
October 15, 2020

Potential COVID-19 Applications of Immunophotonics’ Leading Drug Candidate, IP-001, Being Researched at the University of Oklahoma

OU Daily at the University of Oklahoma recently published a story on research being conducted by Dr. Wei R. Chen...
Read More
October 5, 2020

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors

October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a...
Read More